Glaxo India has just declared its financial results for nine months ended 30th September’01. As the merger of the company with SmithKline Pharma became effective from the beginning of the calendar year, the performance of the company is inclusive with that of SmithKline Beecham Pharma Ltd.
On a merged basis, the company declared a drop in turnover by around 13% and drop in PBT by around 36%. Operating margins are finding difficult to cross the double-digit mark.
Apart from sluggish domestic pharma market, the poor performance of the company has been due to three major reasons:
Both the companies initiated a major rejuvenation to align their product portfolio and focus on high margin products. In this exercise, Glaxo did away with a number of low margin products.
Glaxo India also undertook a restructuring exercise in terms of shifting its manufacturing base from high cost centers, strategic change in sales and marketing structure and higher focus on creating brands. The sales division of the company was changed to ‘therapy focused’ marketing.
Glaxo declared a major VRS drive to achieve operational cost benefits with that of SmithKline Pharma. It also attempted to restructure salary structure differences between the two organisations to achieve smooth integration.
The company has already incurred VRS and integration/restructuring activities related cost of Rs 80 m and Rs 102 m respectively, till date. The company is expected to incur an additional VRS cost of Rs 750 m on its Worli factory in the coming quarters.
A new entity Glaxo SmithKline Beecham Ltd (GSK) will be created and soon be listed on the bourses. The shareholders of Glaxo and SmithKline would be allotted shares in GSK Ltd in the ratio of 2:1 (i.e. 1 share of Glaxo= 1 share of GSK and 2 share of SmithKline = 1 share of GSK Ltd). The merger would become effective on the BSE on November 9, 2001.
Assuming that additional VRS expenses would be incurred in FY02 in the books of GSK India and excluding any extra-ordinary gains from sale of property, GSK’s snapshot can be depicted as shown in the table below.
GSK India - What would it look like
Sales (Rs m)
Net Profit (Rs m)*
Expected EPS (Rs)
Current Market Cap. (Rs m)
(* After deducting Rs 750 m on account of expected VRS expenses)
In the near term, the financials of the company are expected to suffer from the integration pain. Also, the operational cost benefits from the merger are expected to take time before they become visible.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407